Building on its retinal disease expertise, Regeneron signs eye-focused gene therapy pact with German biotech
Regeneron beefed up its gene therapy capabilities Wednesday, signing a new deal with the German biotech ViGeneron.
The similarly named — but unrelated — companies announced the collaboration early Wednesday morning, one which would see ViGeneron receive undisclosed upfront and milestone payments in exchange for Regeneron getting access to its suite of recombinant adeno-associated virus vectors.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.